600276 恒瑞医药 Deep Research

当前结论

Research conclusion: 继续观察.
Trade conclusion: 只观察.
Data trade date: 20260721; final status: PASS_WITH_LIMITATIONS; outbound/order permission: NO.

较上一交易日变化

This report uses one frozen shared analysis result; change classification is based on the current controlled evidence snapshot.

评分、风险等级和交易定位

Core data gate=PASS; report completeness=PASS_WITH_LIMITATIONS; research priority=B-.

公司和主营业务画像

公司=恒瑞医药; 证券代码=600276.SH; 板块=SH_MAIN；市场=主板。
行业=化学制药；主营分部=代谢和心血管、免疫和呼吸系统、其他业务、其他主营业务、神经科学；产品/服务=代谢和心血管, 免疫和呼吸系统, 其他业务, 其他主营业务, 神经科学, 肿瘤类, 造影剂。
商业模式=化学制药；产业链定位=化学制药相关的代谢和心血管、免疫和呼吸系统、其他业务、其他主营业务、神经科学业务环节；收入构成状态=DISCLOSED_FINA_MAINBZ。
上市日期=20001018；上市年限=25.75；信息完整性=COMPLETE。
业务标签=创新药, 医药；数据来源=stock_basic, fina_mainbz。

主营业务与收入结构

代谢和心血管: revenue=2436392215.39; profit=1795325593.69.
免疫和呼吸系统: revenue=861722595.87; profit=729152844.89.
其他业务: revenue=3615967846.15; profit=3437203131.42.
其他主营业务: revenue=759229178.73; profit=411131073.74.
神经科学: revenue=4291837529.76; profit=3550706386.51.
肿瘤类: revenue=16671093834.94; profit=15584717995.80.
造影剂: revenue=2993172992.99; profit=1758523352.35.

多期财务趋势

Annual series (ANNUAL):
20251231: revenue=31629416193.83; revenue_yoy=13.02%; parent_net_profit=7711054811.98; parent_net_profit_yoy=21.69%; deduct_profit=7413405567.05; gross_margin=86.21%; net_margin=24.40%; ROE=14.44%; OCF=11235378130.63.
20241231: revenue=27984605342.06; revenue_yoy=22.63%; parent_net_profit=6336527014.75; parent_net_profit_yoy=47.28%; deduct_profit=6177966481.30; gross_margin=86.25%; net_margin=22.64%; ROE=14.74%; OCF=7422753038.71.
20231231: revenue=22819784741.31; revenue_yoy=7.26%; parent_net_profit=4302435930.05; parent_net_profit_yoy=10.14%; deduct_profit=4141262764.05; gross_margin=84.55%; net_margin=18.75%; ROE=10.99%; OCF=7643665074.52.
20221231: revenue=21275270681.52; revenue_yoy=-17.87%; parent_net_profit=3906304390.78; parent_net_profit_yoy=-13.77%; deduct_profit=NOT_AVAILABLE (controlled source unavailable); gross_margin=NOT_AVAILABLE (controlled source unavailable); net_margin=NOT_AVAILABLE (controlled source unavailable); ROE=NOT_AVAILABLE (controlled source unavailable); OCF=1265264631.93.
20211231: revenue=25905526375.80; revenue_yoy=-6.59%; parent_net_profit=4530217550.47; parent_net_profit_yoy=-28.41%; deduct_profit=4200699248.35; gross_margin=85.56%; net_margin=17.31%; ROE=13.83%; OCF=4218816053.27.
Quarterly series (QUARTERLY_CUMULATIVE and SINGLE_QUARTER):
20260331 cumulative: revenue=8140565320.77; parent_net_profit=2282268233.13; single_quarter_revenue=8140565320.77; single_quarter_parent_net_profit=2282268233.13.
20250930 cumulative: revenue=23188081928.77; parent_net_profit=5751169537.65; single_quarter_revenue=7426888299.87; single_quarter_parent_net_profit=1301063153.19.
20250630 cumulative: revenue=15761193628.90; parent_net_profit=4450106384.46; single_quarter_revenue=8555582506.18; single_quarter_parent_net_profit=2576050864.48.
20250331 cumulative: revenue=7205611122.72; parent_net_profit=1874055519.98; single_quarter_revenue=7205611122.72; single_quarter_parent_net_profit=1874055519.98.
20240930 cumulative: revenue=20189303845.10; parent_net_profit=4619575874.29; single_quarter_revenue=6588569730.33; single_quarter_parent_net_profit=1187827776.19.
20240630 cumulative: revenue=13600734114.77; parent_net_profit=3431748098.10; single_quarter_revenue=7603200202.63; single_quarter_parent_net_profit=2062818850.25.
20240331 cumulative: revenue=5997533912.14; parent_net_profit=1368929247.85; single_quarter_revenue=5997533912.14; single_quarter_parent_net_profit=1368929247.85.
20230930 cumulative: revenue=17013632174.61; parent_net_profit=3473779150.73; single_quarter_revenue=5845253168.48; single_quarter_parent_net_profit=1165514103.01.

盈利能力

Gross margin trend=UP; net margin trend=UP; ROE trend=UP; deduct profit ratio=0.95; non-recurring effect=109869428.59.

现金流与资产质量

OCF/parent profit=0.34; inventory growth=19.40%; receivable growth=2.17%.
Inventory=2886056361.00; receivables=5021464384.51; debt ratio=10.02%; interest-bearing debt=67474747.78; cash coverage=600.62.

估值分析

PE_TTM_ACTUAL=44.90multiple; PE_STATIC_LATEST_ANNUAL=47.28multiple; PE_FORWARD_FORECAST=NOT_AVAILABLE (NO_STRUCTURED_FORECAST_PROFIT); PB_LATEST=5.73multiple; PS_TTM=11.20multiple.
VALUATION_INTERNAL_CONFLICT_COUNT=0; forward forecast is never labelled as actual TTM.
Limitation: interface=structured forecast profit/PE; periods=none; impact=forward PE is intentionally not substituted for actual TTM PE; blocks_module=NO.

估值情景

CURRENT_PROFIT: premise=latest actual TTM profit; PE sensitivity=44.90multiple; actual-TTM-only=YES.
NORMALIZED_PROFIT: premise=actual TTM profit normalized only as sensitivity, not a forecast; PE sensitivity=39.05multiple; actual-TTM-only=YES.
CYCLE_DOWNTURN_PROFIT: premise=actual TTM profit stress sensitivity, not a forecast; PE sensitivity=64.15multiple; actual-TTM-only=YES.

基本面核心矛盾

Bear case / counterevidence: 恒瑞医药: 恒瑞医药 risk context: 交易风险：短线趋势；若资金与价格继续分歧，交易动作维持观察。 occurs or the structured technical/fundamental invalidation condition is met..

行业与主线

Industry=PHARMA_CORE; cycle drivers=创新药, 医药.

直接同行对比

DIRECT_PEER_UNIVERSE:
国药一致: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
ST海王: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
丰原药业: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
派林生物: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
英特集团: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
丽珠集团: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
四环生物: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
万泽股份: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
海南海药: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
东北制药: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
EXTENDED_PEER_UNIVERSE:
No extended peer context is available.

技术面

bars=320/250; trend=UPTREND; close=55.57; MA5/10/20/60/120=55.41/55.35/53.75/51.89/54.25.
20/60/120/250-day high=58.00/58.87/62.38/74.04; low=48.43/45.26/45.26/45.26.
drawdown=-24.95%; volume_percentile=90.00%; RSI14=58.78; ATR14=2.68; volatility20=3.30%.
support=48.43; resistance=58.00.

资金流和市场情绪

| Date | Pct change | Turnover | Main net amount | Main net / turnover | |---|---:|---:|---:|---:| | 20260721 | -1.15% | 5269033.29 | -67401.96 | -1.28% |

1/3/5/10/20-day main net amount: -67401.96 / NOT_AVAILABLE (controlled source unavailable) / NOT_AVAILABLE (controlled source unavailable) / NOT_AVAILABLE (controlled source unavailable) / NOT_AVAILABLE (controlled source unavailable).
Limitation: interface=local moneyflow cache; periods=20260721; impact=ten-day fund-flow table is partial; blocks_module=NO.
Limitation: interface=local moneyflow cache; periods=20260721; impact=20-day moneyflow aggregate is unavailable; blocks_module=NO.

龙虎榜

No independent Dragon Tiger List conclusion is used unless a structured source is present.

事件与公告证据

No structured announcement item is available.
Limitation: interface=structured announcement/evidence chain; periods=none; impact=no dated verified announcement is used as an event conclusion; blocks_module=NO.

催化与验证点

catalyst=创新药; validation_time=NEXT_DISCLOSURE_OR_OPERATING_DATA; validation_data=company disclosure or audited operating/financial data; conditions=named industry driver improves or remains verified; invalidation=named industry driver weakens or lacks verified evidence.
catalyst=医药; validation_time=NEXT_DISCLOSURE_OR_OPERATING_DATA; validation_data=company disclosure or audited operating/financial data; conditions=named industry driver improves or remains verified; invalidation=named industry driver weakens or lacks verified evidence.

风险与反证

恒瑞医药 risk context: 交易风险：短线趋势；若资金与价格继续分歧，交易动作维持观察。
恒瑞医药 risk context: 行业风险：板块强度和核心股表现必须与 peer_universe_id 同口径复核。
恒瑞医药 risk context: 估值风险：估值样本不足时不输出强判断
恒瑞医药 risk context: 事件证伪风险：财务数据更新需要公告标题、披露日、公告日和报告期补齐后复核。

情景推演

Bull case=恒瑞医药: 创新药 improves and controlled financial/market evidence remains aligned.; base case=恒瑞医药: 创新药 remains within the latest controlled evidence range; continue observation only.; bear case=恒瑞医药: 恒瑞医药 risk context: 交易风险：短线趋势；若资金与价格继续分歧，交易动作维持观察。 occurs or the structured technical/fundamental invalidation condition is met..

交易计划与观察纪律

Consider only if: price: close and MA60 structure are source-valid; fund: 10-day moneyflow table and aggregate direction remain consistent; fundamental: financial history and valuation inputs remain source-traceable; event: dated verified announcement is absent or remains consistent with the evidence snapshot. Invalidation: 中期支撑尚在，但短线转弱；资金分歧，今天不能证明承接；守住 MA20=54.05，中期支撑尚在但短线转弱.

仓位与执行约束

Research output only. It does not send, publish, trade, connect to a broker, or place orders.

数据状态

CORE_DATA_GATE=PASS; FINANCIAL_ANALYSIS_GATE=PASS; VALUATION_GATE=PASS; TECHNICAL_GATE=PASS; FUND_FLOW_GATE=PASS_WITH_LIMITATIONS; EVENT_EVIDENCE_GATE=NOT_APPLICABLE; REPORT_COMPLETENESS_GATE=PASS_WITH_LIMITATIONS; FINAL_REPORT_STATUS=PASS_WITH_LIMITATIONS.

一句话总结

恒瑞医药: research status=PASS_WITH_LIMITATIONS; continue only under the structured evidence and invalidation conditions above.

免责声明

Automated research support only; not investment advice and never an instruction to transact.

600276_恒瑞医药_20260722